Legend Biotech Statistics
Total Valuation
Legend Biotech has a market cap or net worth of $7.40 billion. The enterprise value is $6.54 billion.
Important Dates
The last earnings date was Tuesday, November 12, 2024, before market open.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Legend Biotech has 184.29 million shares outstanding. The number of shares has increased by 6.16% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 184.29M |
| Shares Change (YoY) | +6.16% |
| Shares Change (QoQ) | +0.37% |
| Owned by Insiders (%) | 0.06% |
| Owned by Institutions (%) | 51.17% |
| Float | 81.77M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 14.09 |
| Forward PS | 9.67 |
| PB Ratio | 6.60 |
| P/TBV Ratio | 6.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 12.57 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.98, with a Debt / Equity ratio of 0.31.
| Current Ratio | 4.98 |
| Quick Ratio | 4.48 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.76 |
Financial Efficiency
Return on equity (ROE) is -28.35% and return on invested capital (ROIC) is -14.06%.
| Return on Equity (ROE) | -28.35% |
| Return on Assets (ROA) | -12.28% |
| Return on Capital (ROIC) | -14.06% |
| Revenue Per Employee | $284,876 |
| Profits Per Employee | -$190,651 |
| Employee Count | 1,826 |
| Asset Turnover | 0.29 |
| Inventory Turnover | 27.69 |
Taxes
In the past 12 months, Legend Biotech has paid $2.67 million in taxes.
| Income Tax | 2.67M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.64% in the last 52 weeks. The beta is 0.11, so Legend Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.11 |
| 52-Week Price Change | -37.64% |
| 50-Day Moving Average | 46.86 |
| 200-Day Moving Average | 51.44 |
| Relative Strength Index (RSI) | 32.83 |
| Average Volume (20 Days) | 1,753,904 |
Short Selling Information
| Short Interest | 15.86M |
| Short Previous Month | 11.95M |
| Short % of Shares Out | 12.34% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 11.67 |
Income Statement
In the last 12 months, Legend Biotech had revenue of $520.18 million and -$348.13 million in losses. Loss per share was -$1.92.
| Revenue | 520.18M |
| Gross Profit | -55.14M |
| Operating Income | -351.24M |
| Pretax Income | -287.07M |
| Net Income | -348.13M |
| EBITDA | -340.18M |
| EBIT | -351.24M |
| Loss Per Share | -$1.92 |
Full Income StatementBalance Sheet
The company has $1.21 billion in cash and $346.59 million in debt, giving a net cash position of $865.81 million or $4.70 per share.
| Cash & Cash Equivalents | 1.21B |
| Total Debt | 346.59M |
| Net Cash | 865.81M |
| Net Cash Per Share | $4.70 |
| Equity (Book Value) | 1.12B |
| Book Value Per Share | 6.09 |
| Working Capital | 1.08B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$157.60 million and capital expenditures -$20.08 million, giving a free cash flow of -$177.68 million.
| Operating Cash Flow | -157.60M |
| Capital Expenditures | -20.08M |
| Free Cash Flow | -177.68M |
| FCF Per Share | -$0.96 |
Full Cash Flow StatementMargins
Gross margin is -10.60%, with operating and profit margins of -67.52% and -66.92%.
| Gross Margin | -10.60% |
| Operating Margin | -67.52% |
| Pretax Margin | -66.41% |
| Profit Margin | -66.92% |
| EBITDA Margin | -65.40% |
| EBIT Margin | -67.52% |
| FCF Margin | -46.21% |